No. The market is so small that for low-volume generics there is usually just one manufacturer. There's also the moat for competitors to surmount, they must prove equivalency of their galenic form, a certification that the incumbent already has had for decades.
Another way of looking at it is that this is the FDA's fault. If the US Congress were to pass a law permitting importation of (generic) drugs from other first world countries with competent drug regulators this problem would not exist.
This is exactly the same thing as happened with Martin Shkreli, as is happening at the moment with nitroglycerin for heart problems and it's all the FDA's fault.
Seems much like countries have strategic oil reserves they need strategy sourcing of medicines. Make sure there are multiple suppliers and negotiate long term deals.
